Vycor Medical, Inc. announced financial results for the year ended December 31, 2025, reporting revenue growth and improved operating performance across its two business units. The company operates through Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, and NovaVision®, which offers therapy programs for visual disorder recovery after stroke or brain injury.
For the year ended December 31, 2025, the company reported revenue of $1,863,400, representing a 17% increase over 2024. The Vycor Medical division generated revenue of $1,796,070, an 18% increase over the previous year, with most growth coming from international markets as part of a key company strategy, though sales growth continued in the United States. Gross profit for 2025 was $1,498,295, an 11% increase over 2024, generating a margin of 83% versus 89% in 2024, attributable to validation, shipping and higher manufacturing costs of new production as well as a higher international sales mix.
Operating profit was $33,900 compared to an operating loss of $(9,145) in 2024, and non-GAAP operating profit was $145,881 compared to $81,245 in 2024. The company reported non-GAAP cash operating expenses of $1,415,226 compared to $1,340,967 in 2024. On a GAAP basis, the company reported operating expenses of $1,527,207, a net loss of $396,796 and a loss of $0.01 per share. Vycor's GAAP operating costs for year ended December 31, 2025 include non-cash depreciation of purchased assets ($63,143) and non-cash stock compensation charges ($48,838).
During 2025, seven new peer-reviewed studies were published on the ViewSite Brain Access System (VBAS), bringing the total published peer-reviewed clinical papers to 50, with an additional 14 other clinical papers. The studies reflected increasing international spread of VBAS clinical data, with papers published in the United States, United Kingdom, Japan and Mexico, all highlighting clinical advantages of VBAS with respect to reduced brain tissue damage, improved patient outcomes and reduced hospital stay. The VBAS system has been approved and used in over 350 hospitals in the US and in numerous countries internationally, and is protected by 49 issued and 8 pending patents.
A new clinical study on NovaVision's NeuroEyeCoach was published during 2025, comparing results from using the program at home with using it in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences between the two settings in activities of daily living improvements, validating NeuroEyeCoach as an effective tool whether used clinically or accessed remotely. This study is important given the significant drive in healthcare systems worldwide to access digital technologies in home settings. The NovaVision division, which remains in development, generated revenues of $67,330 for the year ended December 31, 2024, a decrease of $6,250 or 8% from 2025, and gross margin of 93%, compared to 91% for 2024.
The company's financial performance demonstrates successful execution of its international growth strategy for its neurosurgical device business, while clinical validation continues to build evidence for both its surgical and therapeutic offerings. The shift toward profitability in the Vycor Medical division, combined with growing clinical evidence supporting both VBAS and NovaVision therapies, positions the company for potential expansion as healthcare systems increasingly value both minimally invasive surgical technologies and digital therapeutic solutions that can be delivered remotely. For more information about the company's technologies, visit https://www.vycorvbas.com or https://www.novavision.com.
